cancer center report

(University of Texas M. D. Anderson Cancer Center) Chronic inflammation combines with DNA methylation, a process that shuts down cancer-fighting genes, to promote development of colorectal cancer, scientists at The University of Texas MD Anderson Cancer Center report today in the advance online publication of the journal Nature Medicine.

(University of Texas M. D. Anderson Cancer Center) A large-scale analysis of patients whose myelodysplastic syndrome is related to earlier cancer treatment overturns the notion that all of them have a poor prognosis, researchers from the University of Texas MD Anderson Cancer Center report at the 53rd Annual Meeting of the American Society of Hematology.

(University of Texas M. D. Anderson Cancer Center) An essential protein for normal stem cell renewal also promotes the growth of breast cancer stem cells when it's overproduced in those cells, researchers at the University of Texas MD Anderson Cancer Center report in the February edition of Cancer Cell.

(Vanderbilt University Medical Center) IKK-beta, a component of a pathway involved in melanoma development, may offer new leads for developing targeted melanoma therapies, researchers at Vanderbilt-Ingram Cancer Center report in the Journal of Clinical Investigation.

(University of Texas M. D. Anderson Cancer Center) Oropharyngeal cancer patients whose tumors in the upper part of the throat test positively for the human papillomavirus have better overall survival than patients with HPV-negative disease, researchers from the University of Texas MD Anderson Cancer Center report in a study published in the New England Journal of Medicine.

(University of Texas M. D. Anderson Cancer Center) Researchers from the University of Texas M. D. Anderson Cancer Center report that in a small study of women with advanced or recurrent endometrial cancer, gemcitabine and cisplatin, when used in combination, produced a response rate in fifty percent of patients.

(University of Texas M. D. Anderson Cancer Center) Overexpression of low-molecular-weight (LMW-E) forms of the protein cyclin E renders the aromatase inhibitor letrozole ineffective among women with estrogen-receptor-positive (ER+) breast cancers, researchers from the University of Texas M.

D. Anderson Cancer Center report in Clinical Cancer Research.

(University of Texas M. D. Anderson Cancer Center) Cancer-initiating cells that launch glioblastoma multiforme, the most lethal type of brain tumor, also suppress an immune system attack on the disease, scientists from the University of Texas M.

D. Anderson Cancer Center report in a paper featured on the cover of the Jan. 15 issue of Clinical Cancer Research.

(University of Texas M. D. Anderson Cancer Center) A growth factor that is a common target of cancer drugs also plays an important role in the heart's response to stress, researchers at the University of Texas M.

D. Anderson Cancer Center report online this week in the Journal of Clinical Investigation.

(Georgetown University Medical Center) It's the ultimate goal in the treatment of cancer: tailoring a person's therapy based on his or her genetic makeup.

While a lofty goal, scientists are steadily moving forward, rapidly exploiting new technologies. Researchers at Georgetown Lombardi Comprehensive Cancer Center report a significant advance in this field of research using a new chip that looks for hundreds of mutations in dozen of genes.